Kumar, Divya P.
Caffrey, Rebecca
Marioneaux, Jonathon
Santhekadur, Prasanna K.
Bhat, Madhavi
Alonso, Cristina
Koduru, Srinivas V.
Philip, Binu
Jain, Mukul R.
Giri, Suresh R.
Bedossa, Pierre
Sanyal, Arun J.
Article History
Received: 16 November 2019
Accepted: 19 May 2020
First Online: 9 June 2020
Competing interests
: Divya P. Kumar and Pierre Bedosa: None for this project. Rebecca Caffrey, Jonathan Marioenaux, Prasanna Santhekadur and Madhavi Bhatt: Employee of Sanyal Bio, Cristina Alonso: Employee of OWL, Srinivas Koduru: Employee of Vedic Research, New York, Binu Philip, Mukul Jain and Suresh Giri: Employee of Zydus, Cadilla, Virginia Commonwealth University has ownership interests of Sanyal Bio. Sanyal Bio is a CRO for mouse models of nonalcoholic fatty liver disease, Arun J. Sanyal: President of Sanyal Bio. Other than this role, he has no COI with Zydus Cadilla. He has stock options in Genfit, Akarna, Tiziana, Indalo, Durect Inversago and Galmed. He has served as a consultant to Astra Zeneca, Nitto Denko, Conatus, Nimbus, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck, Valeant, Boehringer-Ingelheim, Bristol Myers Squibb, Lilly, Hemoshear, Zafgen, Novartis, Novo Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Affimune, Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate. Virginia Commonwealth University, where he is a full time employee, also has ownership interests in Sanyal Biotechnology.